임상시험 검체분석에서 GCLP 적용의 중요성과 발전 방향 : 한국 및 글로벌 사례 중심
The Importance and Future Directions of GCLP Application in Clinical Trial Sample Analysis: A Study of Korea and Global Case Studies
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
This study examines the regulatory landscape and impact of implementing Good Clinical Laboratory Prac- tice (GCLP) in clinical trial sample analysis across the United States, Europe, China, and Korea. Clinical trials are essential for drug development, and reliable sample analysis plays a critical role in ensuring data integrity. GCLP integrates the principles of Good Laboratory Practice (GLP) and Good Clinical Practice (GCP) to maintain quality and reliability in clinical laboratory data. In particular, this research highlights how GCLP helps standardize processes and reduce discrepancies in multinational clinical trials. The comparative analysis of regulatory frameworks and the real-world effects of GCLP adoption in these countries provides insights into improving Korea’s clinical trial infrastructure. The study suggests that enhancing GCLP-compliant infrastructure, expanding personnel training, and establishing central labs are crucial steps for Korea to strengthen its global competitiveness. These measures are vital to ensuring data consistency and increas- ing the success rates of clinical trials in a rapidly evolving international regulatory environment.
Abstract
This study examines the regulatory landscape and impact of implementing Good Clinical Laboratory Prac- tice (GCLP) in clinical trial sample analysis across the United States, Europe, China, and Korea. Clinical trials are essential for drug development, and reliable sample analysis plays a critical role in ensuring data integrity. GCLP integrates the principles of Good Laboratory Practice (GLP) and Good Clinical Practice (GCP) to maintain quality and reliability in clinical laboratory data. In particular, this research highlights how GCLP helps standardize processes and reduce discrepancies in multinational clinical trials. The comparative analysis of regulatory frameworks and the real-world effects of GCLP adoption in these countries provides insights into improving Korea’s clinical trial infrastructure. The study suggests that enhancing GCLP-compliant infrastructure, expanding personnel training, and establishing central labs are crucial steps for Korea to strengthen its global competitiveness. These measures are vital to ensuring data consistency and increas- ing the success rates of clinical trials in a rapidly evolving international regulatory environment.
참고문헌 (29)
- "2023 Korea Clinical Trial Statistics Handbook" (2023), Korea National Enterprise for Clinical Trials (KoNECT)
- 2024 Clinical Trial Industry Survey Report, , Korea National Enterprise for Clinical Trials (KoNECT), ~ (2024)
- "Good Clinical Laboratory Practice" (2022), Ministry of Food and Drug Safety (MFDS)
- Department of Health and Human Services, "Code of Federal Regulations, Title 42, Section 493" (1990), Government Printing Office
- Department of Health and Human Services, "Public Health Service Act, Section 263a, 42 U.S.C" (2012), Government Printing Office
- National Institutes of Health, Division of AIDS, "DAIDS guidelines for good clinical laboratory practice standards" (2013), National Institutes of Health
- "Laboratory accreditation program checklists" (2024), College of American Pathologists
- Regulation EU No 536, "2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use", 2014
- Directive 2001, "20", EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations, and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use, European Medicines Agency, pp.2001, ~
- Directive 2005, "28", EC of 8 April 2005 laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorization of the manufacturing or importation of such products, European Medicines Agency, pp.2005, ~
- ISO 15189 : 2022-Medical lab oratories-Requirements for quality and competence, "International Organization for Standardization", ISO, ~ (2022)
- Regulations for the administration of drug clinical trials, , National Medical Products Administration (NMPA), ~ (2020)
- Good clinical practice for drug trials, , National Medical Products Administration (NMPA), ~ (2020)
- Regulations on Good Laboratory Practice for Non-clinical Trials, , Ministry of Food and Drug Safety (MFDS), ~ (2019)
- Regulations on safety of pharmaceuticals, , Ministry of Food and Drug Safety (MFDS), ~ (2019)
- Regulations on the disposal of residual specimens from tests and inspections, , Ministry of Food and Drug Safety (MFDS), ~ (2019)
- 2019 basic plan for inspection of drug clinical trials, "Clinical Trials Policy Division", Ministry of Food and Drug Safety (MFDS), ~ (2019)
- Guidelines on Good Clinical Laboratory Practice (GCLP), , British Association for Research Quality Assurance (BARQA), ~ (2012)
- "Reflection paper on risk based quality management in clinical trials", Compliance Insp. European Medicines Agency, 44, pp.1~15 (2013)
- Ezzelle J, "Guidelines on Good Clinical Laboratory Practice : Bridging operations between research and clinical research laboratories", J Pharm Biomed Anal, 46(1), pp.18~29 (2008)
- GLOBAL BIO-HEALTH INDUSTRY TREND, , Korea Health Industry Development Institute (KHIDI), ~ (2024)
- Lee NY, "Reduction of pre-analytical errors in the clinical laboratory at the University Hospital of Korea through quality improvement activities", Clin Biochem, 70, pp.24~29 (2019)
- Chang, "Status of Pre-analytical Quality Management of Laboratory Tests at Primary Clinics in Korea", Annals of Laboratory Medicine, 43(5), pp.493~502 (2023)
- "Code of Federal Regulations, Title 21, Part 58" (1978), Government Printing Office
- Huang H, "Unveiling quality of clinical trial in China : from concern to confirmation", Cancer Commun, 44(5), pp.576~ (2024)
- Cascone T, "LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC", Ann Oncol, 34(Suppl 2) (2023)
- Polack FP, "Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine", New England journal of medicine, 383(27), pp.2603~2615 (2020)